> Research Use Only (RUO): MK-677 (ibutamoren) is not approved by the FDA for human therapeutic use. All dosage data presented here is derived from published clinical trial literature and is intended solely for researchers conducting authorized studies. This article does not constitute medical advice.
What Is MK-677 (Ibutamoren)?
MK-677, generically known as ibutamoren mesylate (also referenced in literature as MK-0677 and L-163,191), is a non-peptide, orally active growth hormone secretagogue (GHS) developed by Merck in the 1990s. It functions as a potent, selective agonist of the ghrelin receptor (GHS-R1a) in the hypothalamus and pituitary gland.
Unlike the peptide-based GH secretagogues that require subcutaneous injection — GHRP-2, GHRP-6, ipamorelin — MK-677 is a small-molecule spiroindoline compound that resists gastrointestinal enzymatic degradation and achieves meaningful oral bioavailability (estimated at 60-70% in preclinical models). This makes it pharmacologically unique among GH secretagogues studied to date.
For researchers studying the GH/IGF-1 axis, growth hormone deficiency models, sarcopenia, or body composition in aging models, MK-677 offers a practically significant advantage: a single daily oral dose produces measurable, sustained GH and IGF-1 elevation for approximately 24 hours.
For a full mechanistic profile, see our MK-677 Research Profile.
---
Literature-Reported Research Dosages
The clinical evidence base for MK-677 is unusually robust for a research compound that was never brought to final FDA approval. Multiple Phase II and Phase III trials were conducted by Merck and independent research groups across the late 1990s and 2000s, testing dosages ranging from 5 mg to 25 mg daily.
10 mg/day — The Minimum Effective Dose
Initial dose-response studies conducted in healthy elderly subjects established that 10 mg/day produces statistically significant, sustained increases in serum IGF-1 (approximately 40-55% above baseline) without the more pronounced metabolic effects observed at higher doses.
In the bone turnover study published in The Journal of Clinical Endocrinology & Metabolism (Nass et al., 1999; PubMed ID: 10404019), subjects receiving 10 mg showed meaningful increases in bone remodeling markers including osteocalcin and C-terminal cross-linked telopeptide of type I collagen — evidence of anabolic bone metabolism stimulation.
For research protocols where the primary endpoint is demonstrating GH/IGF-1 elevation with minimal confounding metabolic effects, 10 mg/day represents the lower bound of a pharmacodynamically meaningful dose.
25 mg/day — The Standard Research Dose
The 25 mg/day dose is the most comprehensively studied and consistently used dosage across MK-677 clinical trials. Key findings include:
- •IGF-1 elevation: 55-89% sustained increase above baseline across multiple study populations
- •GH pulse amplitude: 2-5-fold increase in peak GH levels from a single dose (Chapman et al., 1996)
- •Body composition (Nass et al., 2008): Fat-free mass increased by 1.1 kg versus a decrease of 0.5 kg in the placebo arm (p < 0.001) over 12 months
- •Bone density: Increased bone mineral density consistent with elevated bone remodeling over 2-year follow-up
- •Sleep architecture (Murphy et al., 1998): Statistically significant increase in REM sleep duration; modest increase in slow-wave sleep
The landmark Nass et al. (2008) two-year randomized trial — published in the Annals of Internal Medicine (PubMed ID: 18981485) — remains the longest and most rigorous human study of MK-677. Sixty-five healthy adults aged 60-81 were randomized to 25 mg/day or placebo in a modified crossover design. Sustained IGF-1 elevation was confirmed at 24 months without evidence of tachyphylaxis (tolerance), and no pituitary suppression was observed — a meaningful finding distinguishing MK-677 from recombinant somatropin.
5 mg/day — Sub-Threshold Dose
A 5 mg/day arm was included in one functionally-impaired elderly study (PubMed ID: 10404019). Subjects on 5 mg initially advanced to 25 mg at week 2, suggesting the investigators did not consider 5 mg a standalone protocol dose. Researchers studying dose-response relationships may include it as a low-arm control, but standalone protocols at this dose are not well represented in the literature.
Titration Approach
Consistent with the clinical trial protocols, a titration approach — initiating at 10 mg/day for 1-2 weeks before advancing to 25 mg/day — is represented in the research literature as a method to assess individual responses to hunger stimulation and water retention before committing to the standard 25 mg/day research dose.
---
Oral Administration: No Reconstitution Required
A key feature distinguishing MK-677 from peptide-based GH secretagogues is that no reconstitution is required. Peptide GHSs (GHRP-2, GHRP-6, ipamorelin, CJC-1295) are lyophilized powders that must be reconstituted with bacteriostatic water, require sterile injection technique, and are destroyed by gastric acid if taken orally.
MK-677 is typically supplied as:
- •Oral capsules or tablets (most common in research supply)
- •Liquid oral solution (less common)
Both forms are administered orally. No mixing, no syringes, no BAC water, no sterile technique required.
Fasting state consideration: Some research protocols note that fasting administration (at least 2 hours post-meal) may maximize the GH pulse amplitude, consistent with how endogenous ghrelin functions — ghrelin rises in the fasted state. However, the clinical significance of the fed vs. fasted timing difference has not been quantified in a dedicated study, and many trials administered MK-677 without strict fasting requirements.
---
Timing Protocols from Research: Pre-Sleep Administration
The approximately 24-hour half-life of MK-677 means that timing is less pharmacokinetically critical than it is for short-acting injectable GHSs. A once-daily dose maintains receptor occupation throughout the day regardless of when it is taken.
However, pre-sleep administration (30-60 minutes before intended sleep onset) has emerged as the predominant research timing protocol, for two interconnected physiological reasons:
1. Alignment with Natural Nocturnal GH Pulse
Growth hormone is secreted in pulses, with the largest endogenous GH pulse occurring during slow-wave sleep (SWS) in the first third of the night. This is a well-established feature of the hypothalamic-pituitary-GH axis.
MK-677 augments GH pulse amplitude rather than producing a continuous flat GH elevation. Bedtime dosing positions the peak ghrelin receptor agonism to temporally overlap with this natural nocturnal GH pulse, potentially amplifying the body's existing pulsatile release pattern rather than creating an out-of-phase daytime GH surge.
Based on the pharmacokinetics characterized in Chapman et al. (1996), this pre-sleep timing rationale is pharmacologically coherent, though a dedicated timing-comparison study has not been published to date.
2. Appetite Stimulation Mitigation
One of the most consistently reported side effects of MK-677 at 25 mg/day is significant appetite stimulation — an expected consequence of ghrelin receptor agonism (ghrelin is the endogenous "hunger hormone"). For researchers studying body composition endpoints, uncontrolled appetite stimulation is a confounding variable.
Administering MK-677 before sleep effectively places the period of peak ghrelin receptor agonism during a fasted sleep period, when food intake is not occurring. Morning administration, by contrast, occurs at a time when food choices and caloric intake are active research variables.
---
Research Cycling Approaches: What the Long-Term Data Shows
The published clinical trial literature provides direct data on long-term, continuous administration. The Nass 2008 two-year trial confirmed:
- •No tachyphylaxis — no receptor downregulation or IGF-1 tolerance at 25 mg/day through 24 months
- •Sustained fat-free mass preservation maintained in the crossover arm across both years
- •Bone mineral density improvements consistent at 12 and 24 months
This distinguishes MK-677 from some other GH secretagogues where continuous use is associated with diminishing receptor sensitivity.
The non-clinical research literature describes cycling protocols of 8-12 weeks on / 4-6 weeks off, based on the rationale that:
1. Subjective effects (sleep quality, appetite normalization) may habituate after 2-3 months even when objective IGF-1 elevation is maintained
2. The glucose/insulin sensitivity effect documented in Nass 2008 (fasting glucose increase of approximately 5 mg/dL) may benefit from periodic interruption
Researcher note: For protocols designed to replicate the clinical trial literature and study chronic effects, continuous daily administration is the validated approach. Cycling protocols are derived from non-clinical practice patterns and have not been formally tested in human trials.
---
Comparison to Injectable Peptide GH Secretagogues in Research
For researchers designing GH axis studies, the choice of secretagogue fundamentally changes the experimental model. Here is how MK-677 compares to the most commonly studied injectable GHS peptides:
| Parameter | MK-677 (Ibutamoren) | GHRP-2 / GHRP-6 | Ipamorelin |
|---|---|---|---|
| Route | Oral | Injectable (SC) | Injectable (SC) |
| Half-life | ~24 hours | 15-30 minutes | ~2 hours |
| Dosing frequency | Once daily | 2-3x daily | 1-3x daily |
| GH release pattern | Sustained elevation + amplified nocturnal pulse | Sharp, short-duration pulses | Cleaner selective pulse |
| IGF-1 elevation | 40-89% (dose-dependent) | Variable; acute spikes | Variable; dose-dependent |
| Appetite stimulation | Significant | Significant (GHRP-6 > GHRP-2) | Minimal |
| Cortisol / prolactin | Mild elevation | More pronounced (GHRP-2/6) | Minimal |
| Insulin sensitivity | Worsened in clinical trials | Less documented | Less documented |
| Reconstitution required | No | Yes (BAC water) | Yes (BAC water) |
| Oral bioavailability | ~60-70% | Effectively 0% | Effectively 0% |
| Longest human trial | 2 years (Nass 2008) | No comparable long-term data | Limited |
Key research consideration: GHRP-2 and GHRP-6 have additional activity at the CD36 receptor and produce more cortisol stimulation than MK-677. Ipamorelin was specifically engineered for GH selectivity — it does not meaningfully stimulate cortisol or prolactin — but has a much shorter half-life and requires injection. MK-677's primary research advantage is its oral convenience and the depth of its clinical evidence base; its primary limitation is the more pronounced glucose and appetite effects compared to selective injectable GHSs.
---
Storage and Handling
Capsule / Tablet Form
- •Store at room temperature (15-25 degrees C / 59-77 degrees F)
- •Protect from moisture and direct light
- •Keep in original sealed container
- •No refrigeration required under normal storage conditions
- •Do not use past marked expiration date
Liquid Oral Solution
- •Refrigerate after opening (2-8 degrees C)
- •Protect from light (amber container preferred)
- •Check product-specific stability data from supplier
Key Differences from Peptide GHSs
Peptide GH secretagogues (lyophilized) require refrigeration before reconstitution and use within a defined window after reconstitution (typically 28 days refrigerated). MK-677 has more straightforward storage requirements as a small-molecule compound, making it operationally simpler in research settings where cold-chain logistics are a consideration.
---
Price Comparison Across Suppliers
MK-677 pricing varies significantly across research chemical suppliers based on form (capsule vs. liquid), purity certification, and quantity. For current pricing and supplier quality ratings, see our live comparison tool:
Compare MK-677 Prices Across Suppliers
When evaluating suppliers, researchers should look for:
- •Third-party certificate of analysis (CoA) from an independent laboratory
- •HPLC purity 98% or greater
- •Transparent sourcing and batch documentation
---
Research Use Only (RUO) Disclaimer
MK-677 (ibutamoren mesylate) is a research compound. It is not approved by the US Food and Drug Administration (FDA) for any therapeutic use in humans. It is not a dietary supplement. Sale is restricted to licensed researchers and institutions for use in authorized in vitro and in vivo research protocols only.
All clinical dosage data cited in this article is drawn from published peer-reviewed research. This content is provided for educational and research planning purposes only. It does not constitute medical advice, and should not be interpreted as a recommendation for human self-administration. Researchers must comply with all applicable local, national, and institutional regulations governing the use of research chemicals.
---
Key Clinical References
- •Chapman IM et al. (1996). Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology & Metabolism.
- •Nass R et al. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of Internal Medicine. PubMed: 18981485
- •Murphy MG et al. (1998). MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. Journal of Clinical Endocrinology & Metabolism. PubMed: 9467534
- •Nass R et al. (1999). Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. PubMed: 10404019